MARKET

BLRX

BLRX

Biolinerx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.450
+0.210
+16.94%
After Hours: 1.440 -0.01 -0.69% 16:38 05/26 EDT
OPEN
1.260
PREV CLOSE
1.240
HIGH
1.450
LOW
1.220
VOLUME
222.45K
TURNOVER
0
52 WEEK HIGH
3.619
52 WEEK LOW
1.010
MARKET CAP
69.13M
P/E (TTM)
-3.0983
1D
5D
1M
3M
1Y
5Y
BLRX: First Quarter 2022 Operational and Financial Results
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT On May 11, 2022, BioLineRx Ltd. (NASDAQ:BLRX) reported 1Q:22 operational and financial results in a press release concurrent with the filing of Form 6-K . A conference call and webcas...
Zacks Small Cap Research · 05/12 14:16
--Oppenheimer Adjusts BioLineRx Price Target to $7 From $10, Maintains Outperform Rating
MT Newswires · 05/12 10:44
BRIEF-Biolinerx Reports First Quarter 2022 Financial Results And Provides Corporate Update
reuters.com · 05/11 11:09
biolinerx GAAP EPS of -$0.02
biolinerx press release (NASDAQ:BLRX): Q1 GAAP EPS of -$0.02. Ended the first quarter on solid financial footing, with cash and cash equivalents of $50.6 million, sufficient to fund operations, as
Seekingalpha · 05/11 11:09
biolinerx Q1 2022 Earnings Preview
biolinerx (NASDAQ:BLRX) is scheduled to announce Q1 earnings results on Wednesday, May 11th, before market open. The consensus EPS Estimate is -$0.15 (-650.0% Y/Y) and the consensus Revenue Estimate is $0M
Seekingalpha · 05/10 16:19
Notable earnings before Wednesday's open
OTCQX:ADRNY, AGFY, BKSY, BLRX, DNUT, OTCPK:EONGY, EVGO, EXK, FLNG, FREY, FVRR, GMAB, ICL, INVZ, KRNT, LIVE, MCFT, OTCPK:NLLSF, NOMD, ONDS, PDSB, PFGC, PIRS, PRGO, PSFE, OTCPK:SPNX, TAK, TM, TRVN, WEN,
Seekingalpha · 05/10 14:33
BioLineRx to Report First Quarter 2022 Results on May 11, 2022
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended March 31, 2022 on Wednesday, May 11, 2022, before the US ...
PR Newswire · 05/05 11:00
BLRX: 2021 Results
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT
Benzinga · 03/22 12:00
More
No Data
Learn about the latest financial forecast of BLRX. Analyze the recent business situations of Biolinerx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BLRX stock price target is 11.08 with a high estimate of 19.00 and a low estimate of 7.00.
High19.00
Average11.08
Low7.00
Current 1.580
EPS
Actual
Estimate
-0.13-0.10-0.06-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 52
Institutional Holdings: 2.78M
% Owned: 5.83%
Shares Outstanding: 47.68M
TypeInstitutionsShares
Increased
9
234.41K
New
6
81.45K
Decreased
4
31.52K
Sold Out
5
222.98K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Director
Aharon Schwartz
Chief Executive Officer
Philip Serlin
Chief Financial Officer
Mali Zeevi
Vice President
Ella Sorani
Vice President
Abi Vainstein-Haras
Vice President - Business Development
Hillit Mannor Shachar
Director
Michael Anghel
Director
Barbara-Jean Bormann
Director
Raphael Hofstein
Director
Sandra Panem
Non-Executive Director
Nurit Benjamini
Non-Executive Director
Avraham Molcho
No Data
No Data
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Webull offers kinds of BioLine RX Ltd - ADR stock information, including NASDAQ:BLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLRX stock methods without spending real money on the virtual paper trading platform.